Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-α2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
1. A method of treating a cancer that expresses IGF-1R comprising:
a) administering a complex to an individual with the cancer, wherein the complex comprises:
(i) an anti-IGF-1R IgG antibody or antigen-binding fragment thereof attached to one or more anchor domain (AD) moieties from an AKAP protein; and
(ii) two or more copies of an effector attached to a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the effector is a second antigen-binding antibody fragment or a cytokine; and
b) administering a therapeutic agent to the individual;
wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.
2. The method of claim 1 , wherein the second antigen-binding antibody fragment is selected from the group consisting of an anti-IGF-1R antigen-binding antibody fragment, an anti-TROP2 antigen-binding antibody fragment and an anti-CEACAM6 antigen-binding antibody fragment.
3. The method of claim 1 , wherein the second antigen-binding antibody fragment binds to a tumor-associated antigen selected from the group consisting of carbonic anhydrase IX, CSAp, CD1, CD1a, CD2, CD3, CD4, CD5, CD8, CD11A, CD14, CD15, CD16, CD18, CD19, CD20, IGF-1R, CD21, CD22, CD23, CD25, CD29, CD30, CD32b, CD33, CD37, CD38, CD40, CD4OL, CD45, CD46, CD52, CD54, CD55, CD59, CD64, CD66a-e, CD67, CD70, CD74, CD79a, CD80, CD83, CD95, CD126, CD133, CD138, CD147, CD154, CEACAM5, CEACAM6, B7, ED-B fibronectin, Factor H, FHL-1, Flt-3, folate receptor, GRO-β, HMGB-1, hypoxia inducible factor (HIF), HM1.24, insulin-like growth factor-1 (ILGF-1), IFN-γ, IFN-α, IFN-β, IL-2, IL-4R, IL-6R, IL-13R, IL-15R, IL-17R, IL-18R, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, IL-25, IP-10, MAGE, mCRP, MCP-1, MIP-1A, MIP-1B, MIF, MUC1, MUC2, MUC3, MUC4, MUC5ac, PAM4 antigen, NCA-95, NCA-90, PSMA, EGP-1, EGP-2, AFP, Ia, HLA-DR, tenascin, Le(y), RANTES, T101, TAC, Tn antigen, Thomson-Friedenreich antigens, tumor necrosis antigens, TNF-α, TRAIL receptor R1, TRAIL receptor R2, VEGFR, EGFR, P1GF, complement factors C3, C3a, C3b, C5a, C5, and an oncogene product.
4. The method of claim 1 , wherein the cytokine is interferon-α2b.
5. The method of claim 1 , wherein the cytokine is selected from the group consisting of human growth hormone, N-methionyl human growth hormone, bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH); hepatic growth factor; prostaglandin, fibroblast growth factor; prolactin; placental lactogen, OB protein; tumor necrosis factor-α, tumor necrosis factor-β; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; thrombopoietin (TPO); NGF-β; platelet-growth factor; TGF-α, TGF-β; insulin-like growth factor-I, insulin-like growth factor-II; erythropoietin (EPO); osteoinductive factors; an interferon, interferon-α, interferon-β, interferon-γ; macrophage-CSF (M-CSF); IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-21, IL-25, kit-ligand, angiostatin, thrombospondin, endostatin, and tumor necrosis factor.
6. The method of claim 1 , wherein the anti-IGF-1R antibody or antigen-binding fragment thereof (i) binds to human IGF-1R; (ii) does not bind to human insulin receptor (IR); (iii) is not an agonist of IGF-1R; (iv) does not block binding of IGF-1 or IGF-2 to an isolated IGF-1R; and (v) neutralizes the activation of IGF-1R by IGF-1 in intact cells.
7. The method of claim 1 , wherein the anti-IGF-1R antibody or antigen-binding fragment thereof binds to the first half of the cysteine-rich domain of IGF-1R, between amino acid residues 151 and 222 of human IGF-1R.
8. The method of claim 1 , wherein the anti-IGF-1R antibody or antigen-binding fragment thereof competes for binding to IGF-1R with a murine antibody comprising the heavy chain CDR sequences CDR1 (DYYMY, SEQ ID NO:85), CDR2 (YITNYGGSTYYPDTVKG, SEQ ID NO:86) and CDR3 (QSNYDYDGWFAY, SEQ ID NO:87) and the light chain CDR sequences CDR1 (KASQEVGTAVA, SEQ ID NO:88), CDR2 (WASTRHT, SEQ ID NO:89) and CDR3 (QQYSNYPLT, SEQ ID NO:90).
9. The method of claim 1 , wherein the anti-IGF-1R antibody or antigen-binding fragment thereof comprises the heavy chain CDR sequences CDR1 (DYYMY, SEQ ID NO:85), CDR2 (YITNYGGSTYYPDTVKG, SEQ ID NO:86) and CDR3 (QSNYDYDGWFAY, SEQ ID NO:87) and the light chain CDR sequences CDR1 (KASQEVGTAVA, SEQ ID NO:88), CDR2 (WASTRHT, SEQ ID NO:89) and CDR3 (QQYSNYPLT, SEQ ID NO:90).
10. The method of claim 9 , wherein the anti-IGF-1R antibody or antigen-binding fragment thereof comprises the heavy chain variable region amino acid sequence of SEQ ID NO:94 and the light chain variable region amino acid sequence of SEQ ID NO:95.
11. The method of claim 1 , wherein the anti-IGF-1R antibody is a chimeric antibody, a humanized antibody or a human antibody.
12. The method of claim 1 , wherein the cancer is selected from the group consisting of Wilms' tumor, Ewing sarcoma, a neuroendocrine tumor, a glioblastoma, a neuroblastoma, a melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, renal cancer, pancreatic cancer, lung cancer, biliary cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid carcinoma, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and urinary bladder cancer.
13. The method of claim 1 , wherein the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
14. A method of treating a cancer that expresses IGF-1R comprising:
a) administering a complex to an individual with the cancer, wherein the complex comprises:
(i) an anti-IGF-1R IgG antibody or antigen-binding fragment thereof attached to one or more anchor domain (AD) moieties from an AKAP protein, wherein the anti-IGF-1R antibody is conjugated to at least one therapeutic or diagnostic agent; and
(ii) two or more copies of an effector attached to a dimerization and docking domain (DDD) moiety from a human protein kinase A (PKA) regulatory subunit RIα, RIβ, RIIα or RIIβ, wherein the effector is a second antigen-binding antibody fragment or a cytokine;
wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the complex.
15. The method of claim 14 , wherein said therapeutic agent is selected from the group consisting of a radionuclide, an immunomodulator, an anti-angiogenic agent, a cytokine, a chemokine, a growth factor, a hormone, a drug, a prodrug, an enzyme, a pro-apoptotic agent, a photoactive therapeutic agent, a cytotoxic agent, a chemotherapeutic agent and a toxin.
16. The method of claim 15 , wherein the drug is selected from the group consisting of 5-fluorouracil, aplidin, azaribine, anastrozole, anthracyclines, bendamustine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, cladribine, camptothecans, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, estramustine, epipodophyllotoxin, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, gemcitabine, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, lenolidamide, leucovorin, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, nitrosourea, plicomycin, procarbazine, paclitaxel, pentostatin, PSI-341, raloxifene, semustine, streptozocin, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinorelbine, vinblastine, vincristine and vinca alkaloids.
17. The method of claim 15 , wherein the toxin is selected from the group consisting of ricin, abrin, alpha toxin, saporin, ribonuclease (RNase), onconase, DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.
18. The method of claim 15 , wherein the radioisotope is selected from the group consisting of 111 In, 177 Lu, 212 Bi, 211 At, 62 Cu, 67 Cu, 90 Y, 125 I, 131 I, 32 P, 33 P, 47 Sc, 111 Ag, 67 Ga, 142 Pr, 153 Sm, 161 Tb, 166 Dy, 166 Ho, 186 Re, 188 Re, 189 Re, 212 Pb, 223 Ra, 225 Ac, 59 Fe, 75 Se, 77 As, 89 Sr, 99 Mo, 105 Rh, 109 Pd, 143 Pr, 149 Pm, 169 Er, 194 Ir, 198 Au, 199 Au, and 211 Pb.
19. The method of claim 1 , wherein said therapeutic agent is selected from the group consisting of an immunomodulator, an anti-angiogenic agent, a cytokine, a chemokine, a growth factor, a hormone, a drug, a prodrug, an enzyme, a pro-apoptotic agent, a photoactive therapeutic agent, a cytotoxic agent, and a chemotherapeutic agent.
20. The method of claim 19 , wherein the drug is selected from the group consisting of 5-fluorouracil, aplidin, azaribine, anastrozole, anthracyclines, bendamustine, bleomycin, bortezomib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin (CDDP), Cox-2 inhibitors, irinotecan (CPT-11), SN-38, cladribine, camptothecans, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunorubicin, doxorubicin, 2-pyrrolinodoxorubicine (2P-DOX), cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, estramustine, epipodophyllotoxin, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, gemcitabine, hydroxyurea, idarubicin, ifosfamide, L-asparaginase, lenolidamide, leucovorin, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, nitrosourea, plicomycin, procarbazine, paclitaxel, pentostatin, PSI-341, raloxifene, semustine, streptozocin, tamoxifen, temazolomide, transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinorelbine, vinblastine, vincristine and vinca alkaloids.